Bremer Trust National Association cut its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 3.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,555 shares of the medical research company’s stock after selling 307 shares during the period. Bremer Trust National Association’s holdings in Thermo Fisher Scientific were worth $1,318,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Independent Portfolio Consultants Inc. increased its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares in the last quarter. Sharkey Howes & Javer increased its stake in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares in the last quarter. Beacon Trust Co. increased its stake in shares of Thermo Fisher Scientific by 0.6% in the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock worth $341,000 after buying an additional 12 shares in the last quarter. Dumont & Blake Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock worth $849,000 after buying an additional 15 shares in the last quarter. Finally, Azimuth Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock worth $493,000 after buying an additional 25 shares in the last quarter. Institutional investors own 83.52% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded up 0.47% during trading on Monday, hitting $178.06. 259,319 shares of the company’s stock were exchanged. The company has a market cap of $69.46 billion, a P/E ratio of 31.02 and a beta of 1.06. The company has a 50-day moving average of $176.80 and a 200-day moving average of $167.41. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. During the same quarter in the prior year, the company posted $2.03 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. On average, equities analysts expect that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/bremer-trust-national-association-reduces-position-in-thermo-fisher-scientific-inc-tmo/1528211.html.

A number of analysts have issued reports on the stock. Deutsche Bank AG set a $200.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Saturday, June 10th. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Wells Fargo & Company reiterated an “outperform” rating and issued a $200.00 price target (up from $195.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 13th. Jefferies Group LLC reiterated a “hold” rating and issued a $175.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, May 17th. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. One investment analyst has rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $188.56.

In other news, Director Jim P. Manzi sold 1,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the transaction, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,790,226.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jim P. Manzi sold 11,318 shares of the company’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,818 shares of company stock valued at $6,028,985. Corporate insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.